The recurrent translocation t(11; 16)(q23; p13) has been reported to be associated with therapy-related acute leukemia. The MLL gene involved in other 11q23 abnormalities was also rearranged by this translocation. We analyzed two patients with myelodysplastic syndrome with t(11; 16) and showed that the MLL gene on 11q23 was fused with CREB-binding protein (CBP) gene on 16p13 in these patients. The CBP gene encodes a transcriptional adaptor/coactivator protein and it is mutated in patients with Rubinstein-Taybi syndrome. The CBP gene is also involved in acute myeloid leukemia (AML) with t(8; 16)(p11; p13). In-frame MLL-CBP fusion transcripts combine the MLL AT-hook motifs and DNA methyltransferase homology region with a largely intact CBP. Our results combined with the finding of the MOZ-CBP fusion in t(8; 16)-AML suggest that the CBP gene may be associated with leukemogenesis through translocations.

CHROMOSOMAL translocations are the most common genetic events observed in hematopoietic malignancies.1,2 It has been thought that specific genes are associated with specific translocations.3 However, recent molecular and cytogenetic studies have shown that some genes involved in specific translocations are also associated with other translocations, such as the AML1 gene in t(8; 21)-acute myeloid leukemia (AML)4 and t(12; 21)-acute lymphoblastic leukemia (ALL),5 and the NPM gene in t(2; 5)–non-Hodgkin's lymphoma (NHL)6 and the t(3; 5)-myelodysplastic syndrome (MDS),7 and that some tumor-suppressor genes are occasionally associated with chromosomal translocations.8,9 The MLL gene10 (also called ALL-1, HRX, and Htrx-1) has been identified in 11q23 translocations,11-13 and its rearrangement was found in the majority of infant14-16 and secondary leukemias.17,18 This gene forms fusion transcripts with over 10 partner genes.11,12,19,20 However, it remains to be elucidated whether the MLL gene, the partner genes, or the fusion transcripts play a critical role in leukemogenesis. The CREB-binding protein (CBP) gene, encoding a transcriptional adaptor/coactivator protein, resides on 16p1321 and it is mutated in patients with Rubinstein-Taybi syndrome.22 Recently, the CBP gene was found to be translocated in AML with t(8; 16)(p11; p13).23,24 The recurrent translocation t(11; 16) (q23; p13) is associated with therapy-related acute leukemia.17,25 Here we identified that the MLL gene was fused with CBP gene in two patients of MDS with t(11; 16). Our results combined with the finding of the MOZ-CBP fusion in t(8; 16)-AML suggest that the CBP gene may be associated with leukemogenesis through translocations.

Patients.Patient 1, a 2-year-old girl, was diagnosed as refractory anemia with excess of blasts in transformation (RAEB-T). Patient 2, a 6-year-old boy, was initially diagnosed as AML(M2) with t(8; 21)(q22; q22). He achieved a complete remission by chemotherapy including etoposide. After 14 months he developed RAEB-T. Patient samples were obtained at diagnosis from bone marrow (BM) aspirations of both patients with RAEB-T, and their karyotypes showed t(11; 16)(q23; p13) (Fig 1).

Fig. 1.

Schematic partial karyotype of t(11; 16) (q23; p13). The normal chromosomes of nos. 11 and 16 are on the left in each pair. Arrowheads indicate the breakpoints in the translocation chromosome on the right.

Fig. 1.

Schematic partial karyotype of t(11; 16) (q23; p13). The normal chromosomes of nos. 11 and 16 are on the left in each pair. Arrowheads indicate the breakpoints in the translocation chromosome on the right.

Close modal

Cytogenetic studies.The chromosomes of BM cells from patients 1 and 2 were analyzed by the regular trypsin-Giemsa- or Q-banding method as previously described.16,26 

Southern and Northern blot analyses.High-molecular-weight DNA was extracted from BM cells from patient 1 by proteinase K digestion and phenol/chloroform extraction. Ten micrograms of DNA was digested with appropriate restriction enzymes, subjected to electrophoresis on 0.8% agarose gels, transferred to charged nylon filters (Pall BioSupport, Tokyo, Japan), and hybridized to DNA probes labeled by the random hexamer method.16,19 

Poly(A)+ RNA from BM cells of patient 1 was extracted with a Fast Track mRNA Isolation Kit (Invitrogen, San Diego, CA). One microgram of poly (A)+ mRNAs was electrophoresed and transferred onto nylon filters. Blots were hybridized to 32P-labeled probes under the described conditions.19 

A 0.9-kb BamHI fragment (designated probe x) derived from MLL cDNA,27 and a 0.5-kb CBP cDNA (nucleotides 701-1197 from patial sequences of CBP cDNA, GenBank accession no. U47741) were used as probes (Fig 2).

Fig. 2.

Schematic representation of the MLL, CBP, and MLL-CBP fusion proteins, and MLL and CBP cDNA probes and primers (MLL-7S, MLL-11A, CBP-2S, CBP-1A). C/H rich, cysteine/histidine rich; Q rich, glutamine rich. The position of the motifs in CBP were derived from the published protein sequence. The MLL-CBP fusion protein retains the key domains from both proteins.

Fig. 2.

Schematic representation of the MLL, CBP, and MLL-CBP fusion proteins, and MLL and CBP cDNA probes and primers (MLL-7S, MLL-11A, CBP-2S, CBP-1A). C/H rich, cysteine/histidine rich; Q rich, glutamine rich. The position of the motifs in CBP were derived from the published protein sequence. The MLL-CBP fusion protein retains the key domains from both proteins.

Close modal

Reverse transcriptase-polymerase chain reaction (RT-PCR).Total cellular RNA was extracted from BM cells of patients 1 and 2 by the acid guanidine isothiocyanate-phenol-chloroform method.28 Four micrograms of total RNA was reverse transcribed to cDNA in a total volume of 20 μL with random hexamers and 20 U of reverse transcriptase (AMV) (Boehringer Mannheim). One twentieth of the cDNA was amplified by PCR in a total volume of 100 μL with 50 mmol/L KCl, 1.5 mmol/L MgCl2 , 10 mmol/L Tris-HCl (pH 9.0 at room temperature), 25 pmol/L of each primer, 75 μmol/L of each dNTP, and 2.5 U of Taq polymerase (Boehringer Mannheim). After 30 rounds of PCR (30 seconds at 94°C, 30 seconds at 55°C, and 1 minute at 72°C), 5 μL of PCR product was electrophoresed in a 3% agarose gel. Primers used were as follows: MLL-7S, 5′-TCCTCAGCACTCTCTCCAAT-3′; MLL-11A, 5′-TTTGCCTGGAGTTGTGGATC-3′; CBP-2S, 5′-TGAATGGATCTCTTGGGGCT-3′; CBP-1A, 5′-GTTTGCTTGCTCTCGTCTCT-3′ (Fig 2).

Cloning and sequencing of PCR products.PCR products were cloned into the TA cloning vector (Invitrogen). Nucleotide sequences were determined by the fluorometric method (Dye Terminator Cycle Sequencing Kit; Applied Biosystems, Urayasu, Japan).

MLL and CBP genes were involved in t(11; 16)-MDS.Cells from two children with MDS were cytogenetically characterized as t(11; 16)(q23; p13) (Fig 1). We identified the chromosomal breakpoint within the breakpoint cluster region of MLL gene at 11q23 by Southern blotting using a cDNA probe (probe x) (Figs 2 and 3A) that spans exons 5 through 11 in the MLL locus.27 

Fig. 3.

(A) Southern blot of DNA digested with EcoRI and probed with the 0.9-kb fragment of the MLL gene. Control, peripheral lymphocytes. Patient 1 exhibited a rearranged band (arrowhead) with this probe. (B) Northern blot of RNAs from patient 1 and a control leukemic cell line (BALM14) using a 0.5-kb CBP cDNA fragment as a probe. Patient 1 showed an abnormal transcript (arrowhead).

Fig. 3.

(A) Southern blot of DNA digested with EcoRI and probed with the 0.9-kb fragment of the MLL gene. Control, peripheral lymphocytes. Patient 1 exhibited a rearranged band (arrowhead) with this probe. (B) Northern blot of RNAs from patient 1 and a control leukemic cell line (BALM14) using a 0.5-kb CBP cDNA fragment as a probe. Patient 1 showed an abnormal transcript (arrowhead).

Close modal

Chromosome 16 band p13 is involved in the chromosomal aberrations, inv(16)(p13q22) and t(8; 16)(p11; p13), in AML. However, the position of the breakpoint at 16p13 in inv(16) differs from that of the t(8; 16).29 To isolate a gene on chromosome 16p13 that fuses to MLL, we performed Southern and Northern blot analyses using a CBP cDNA probe (Fig 2). Blots that were used to detect MLL rearrangements and expression were rehybridized with a probe containing 0.5-kb of the 9-kb CBP cDNA. This probe contains cDNA sequences from both sides of the breakpoint within the CBP cDNA in t(8; 16)-AML and could thus potentially detect both der(11) and der(16). Southern blotting did not detect any rearrangements with CBP cDNA. To clarify the expression of the CBP transcripts, a CBP probe was examined for hybridization to poly(A)+ mRNAs extracted from cells from patient 1, which showed a normal 9-kb CBP transcript and an additional 12-kb transcript (Fig 3B).

Detection of MLL-CBP fusion transcripts.Using the sense primer on MLL exon 7 (MLL-7S) and the antisense primer on CBP (CBP-1A), we obtained PCR products of 521 bp from patients 1 and 2, and of 407 bp from patient 1 (Fig 4A). Nucleotide sequencing analysis of the three amplified fragments demonstrated 197 bp of MLL exons 7 and 8 in the 5′ region, and 324 bp of CBP exon in the 3′ region of the longer fragment from both patients, and 83 bp of MLL exon 7 in the 5′ region and 324 bp of the CBP exon in the 3′ region of the shorter fragment from patient 1 (Fig 4B). These findings indicate that the two chimeric products are generated by alternative splicing at the MLL gene, which was observed in other 11q23 translocations.30 Only in patient 1 were reciprocal PCR products of CBP-MLL fusion transcripts generated by RT-PCR using the sense primer on CBP (CBP-2S) and the antisense primer on MLL exon 11 (MLL-11A) (Fig 4A and B). The fusion transcripts of MLL-CBP commonly observed were considered to play a critical role in the leukemogenesis of t(11; 16)-MDS.

Fig. 4.

(A) Identification of fusion transcripts by RT-PCR. Primers used were MLL-7S and CBP-1A (MLL-CBP), and CBP-2S and MLL-11A (CBP-MLL). (B) Partial sequences at the chimeric junctions from five cDNAs (MLL, longer and shorter fragments of MLL-CBP, CBP-MLL, and CBP). longer, longer fragment of 521 bp from patients 1 and 2; shorter, shorter fragment of 407 bp from patient 1. Vertical lines indicate the exon-exon junctions of each gene. Arrows indicate the fusion points of each cDNA.

Fig. 4.

(A) Identification of fusion transcripts by RT-PCR. Primers used were MLL-7S and CBP-1A (MLL-CBP), and CBP-2S and MLL-11A (CBP-MLL). (B) Partial sequences at the chimeric junctions from five cDNAs (MLL, longer and shorter fragments of MLL-CBP, CBP-MLL, and CBP). longer, longer fragment of 521 bp from patients 1 and 2; shorter, shorter fragment of 407 bp from patient 1. Vertical lines indicate the exon-exon junctions of each gene. Arrows indicate the fusion points of each cDNA.

Close modal

The t(11; 16) has thus far been reported in two patients with therapy-related ALL and AML.17,25 Chromosomal breakpoints in 11q23 were detected within the MLL breakpoint cluster region by Southern blotting in both patients. In the present study we first identified that the MLL gene was fused to the CBP gene in two MDS-patients with t(11; 16).

The MLL gene, a human homolog of the Drosophila trithorax gene, encodes a protein of 3,972 amino acids (431 kD) containing zinc fingers and AT-hook motifs.11-13 The incidence of MLL gene rearrangements has been shown to be up to 80% of infant acute leukemia.14-16MLL gene rearrangements also occur at very high frequency in secondary acute leukemias induced by treating malignancies with inhibitors of topoisomerase II,17,18 suggesting that a reduction in the activity of topoisomerase II is one of the mechanisms for the occurrence of MLL gene rearrangement. It is noted that the MLL gene is fused with various partner genes by 11q23 chromosome translocations. Up to now, 10 partner genes for MLL have been cloned from leukemia cells with various types of reciprocal translocations, including t(4; 11), t(9; 11) and t(11; 19).11-13,19,20 They include the putative transcriptional factors (AF-4, AF-9, AF-10, AF-17, ENL),11,12,20 a target gene for Ras (AF-6),31 and an RNA polymerase II elongation factor (ELL).32 The functions of the normal MLL gene and the fusion transcripts remain unknown. Only one paper reports that chimeric mice carrying the mouse Mll-AF-9 fusion gene developed AML.33 Rearrangements of the MLL gene found in ALL, AML, and MDS suggest that this gene fused with various partner genes plays a causative role in the dysregulation of differentiation along both lymphoid and myeloid pathways.

The CBP, a family of transcriptional coactivator p300, has an adenoviral oncoprotein E1A binding domain and connects the basal transcriptional machinery to transcriptional factors such as the cyclic-adenosine monophosphate responsive element binding protein (CREB).21 CBP normally associates with p300/CBP-associated factor (P/CAF ) having intrinsic histon acetyltransferase activity.34 P/CAF, and also p300, inhibit cell-cycle progression,34 suggesting that CBP may also be involved in the regulation of cell cycle. Moreover, mutations of CBP lead to the development of Rubinstein-Taybi syndrome,22 whose patients have an increased risk of malignant tumors.35 These findings suggest that CBP may be a tumor-suppressor gene. Fusion of CBP to translocated MOZ sequences is associated with specific subtypes of AML with t(8; 16),23,24 and this leukemogenesis may be also associated with dysfunction of CBP.

A schematic representation of the predicted MLL-CBP fusion proteins is shown in Fig 2, with the predicted MLL-CBP fusion transcripts encoding a protein of 3,618 amino acids containing 1,444 amino acids from MLL (amino acids 1 to 1,444) and 2,174 amino acids from CBP (amino acids 267 to 2,440). The MLL-CBP chimeric protein retains the AT-hook domain, DNA methyltransferase homology region, and a transcriptional repression domain of MLL, and the CREB-, E1A-, TFIIB- and P/CAF-binding domains and the acetyltransferase domain36 of CBP. These findings suggest that one possible explanation for leukemogenesis of t(11; 16)-MDS is the disability of CBP to regulate the cell cycle by structural alteration through fusion with MLL. Further functional analysis of the MLL-CBP fusion gene will provide new insights into leukemogenesis by 11q23 chromosomal translocations.

We thank Prof Y. Igarashi (Department of Pediatrics, Hamamatsu University School of Medicine), Prof M. Yanagisawa (Department of Pediatrics, Faculty of Medicine, University of Tokyo), and I. Kitabayashi (Radiobiology Division, National Cancer Center Research Institute, Tokyo), for their advice and review. We also thank M. Seto (Laboratory of Chemotherapy, Aichi Cancer Center Research Institute) for providing the MLL cDNA probe (probe x), and S. Sohma for her technical assistance.

Supported by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare of Japan, a Grant-in-Aid for Scientific Research on Priority Areas, and Grant-in-Aid for Scientific Research (B) and (C) from the Ministry of Education, Science, Sports and Culture of Japan.

Address reprint requests to Yasuhide Hayashi, MD, Department of Pediatrics, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo 113, Japan.

1
Pui
C-H
Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia.
Blood
76
1990
1449
2
Rowley
JD
Molecular cytogenetics: Rosetta stone for understanding cancer — Twenty-ninth G.H.A. Clowes Memorial Award Lecture.
Cancer Res
50
1990
3816
3
Rabbitts
TH
Chromosomal translocations in human cancer.
Nature
372
1994
143
4
Miyoshi
H
Shimizu
K
Kozu
T
Maseki
N
Kaneko
Y
Ohki
M
t(8; 21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.
Proc Natl Acad Sci USA
88
1991
10431
5
Golub
TR
Barker
GF
Bohlander
SK
Hiebert
SW
Ward
DC
Bray-Ward
P
Morgan
E
Raimondi
SC
Rowley
JD
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Proc Natl Acad Sci USA
92
1995
4917
6
Morris
SW
Kirstein
MN
Valentine
MB
Dittmer
KG
Shapiro
DN
Saltman
DL
Look
AT
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
Science
263
1994
1281
7
Yoneda-Kato
N
Look
AT
Kirstein
MN
Valentine
MB
Raimondi
SC
Cohen
KJ
Carroll
AJ
Morris
SW
The t(3; 5)(q25.1; q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1.
Oncogene
12
1996
265
8
Ladanyi
M
Gerald
W
Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor.
Cancer Res
54
1994
2837
9
Buijs
A
Sherr
S
van Baal
S
van Bezouw
S
van der Plas
D
Geurts van Kessel
A
Riegman
P
Lekanne
Deprez R
Zwarthoff
E
Hagemeijer
A
Translocation (12; 22)(p13; q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11.
Oncogene
10
1995
1511
10
McCabe
NR
Burnett
RC
Gill
HJ
Thirman
MJ
Mbangkollo
D
Kipiniak
M
van Melle
E
Ziemin-van der Poel S
Rowley
JD
Diez
MO
Cloning of cDNAs of the MLL gene that detect DNA rearrangements and altered RNA transcripts in human leukemic cells with 11q23 translocations.
Proc Natl Acad Sci USA
89
1992
11794
11
Tkachuk
DC
Kohler
S
Cleary
ML
Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias.
Cell
71
1992
691
12
Gu
Y
Nakamura
H
Alder
H
Prasad
R
Canaani
O
Cimino
G
Croce
CM
Canaani
E
The t(4; 11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene.
Cell
71
1992
701
13
Djabali
M
Selleri
L
Parry
P
Bower
M
Young
BD
Evans
GA
A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias.
Nature Genet
2
1992
113
14
Rubnitz
JE
Link
MP
Shuster
JJ
Carroll
AJ
Hakami
N
Frankel
LS
Pullen
DJ
Cleary
ML
Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Blood
84
1994
570
15
Pui
C-H
Kane
JR
Crist
WM
Biology and treatment of infant leukemias.
Leukemia
9
1995
762
16
Taki
T
Ida
K
Bessho
F
Hanada
R
Kikuchi
A
Yamamoto
K
Sako
M
Tsuchida
M
Seto
M
Ueda
R
Hayashi
Y
Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia.
Leukemia
10
1996
1303
17
Hunger
SP
Tkachuk
DC
Amylon
MD
Link
MP
Carroll
AJ
Welborn
JL
Willman
CL
Cleary
ML
HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities.
Blood
81
1993
3197
18
Gill
Super HJ
McCabe
NR
Thirman
MJ
Le Beau
MM
Pedersen-Bjergaard
J
Philip
P
Diez
MO
Rowley
JD
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.
Blood
82
1993
3705
19
Taki
T
Hayashi
Y
Taniwaki
M
Seto
M
Ueda
R
Hanada
R
Suzukawa
K
Yokota
J
Morishita
K
Fusion of the MLL gene with two different genes, AF-6 and AF-5α, by a complex translocation involving chromosomes 5, 6, 8, and 11 in infant leukemia.
Oncogene
13
1996
2121
20
Rubnitz
JE
Behm
FG
Downing
JR
11q23 rearrangements in acute leukemia.
Leukemia
10
1996
74
21
Kwok
RPS
Lundblad
JR
Chrivia
JC
Richards
JP
Bächinger
HP
Brennan
RG
Roberts
SGE
Green
MR
Goodman
RH
Nuclear protein CBP is a coactivator for the transcription factor CREB.
Nature
370
1994
223
22
Petrij
F
Giles
RH
Dauwerse
HG
Saris
JJ
Hennekam
RCM
Masuno
M
Tommerup
N
van Ommen
G-JB
Goodman
RH
Peters
DJM
Breuning
MH
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP.
Nature
376
1995
348
23
Borrow
J
Stanton
VP Jr
Andresen
M
Becher
R
Behm
FG
Chaganti
RSK
Civin
CI
Disteche
C
Dube
I
Frischauf
AM
Horsman
D
Mitelman
F
Volinia
S
Watmore
AE
Housman
DE
The translocation t(8; 16)(p11; p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein.
Nature Genet
14
1996
33
24
Reifcnyder
C
Lowell
J
Clarke
A
Pillus
L
Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases.
Nature Genet
14
1996
42
25
Roulston
D
Anastasi
J
Rudinsky
R
Nucifora
G
Zeleznik-Le
N
Rowley
JD
McGavran
L
Tsuchida
M
Hayashi
Y
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8; 21): A report of two cases.
Blood
86
1995
3613
26
Kawamura
M
Kikuchi
A
Kobayashi
S
Hanada
R
Yamamoto
K
Horibe
K
Shikano
T
Ueda
K
Hayashi
K
Sekiya
T
Hayashi
Y
Mutations of the p53 and ras genes in childhood t(1; 19)-acute lymphoblastic leukemia.
Blood
85
1995
2546
27
Yamamoto
K
Seto
M
Komatsu
H
Iida
S
Akao
Y
Kojima
S
Kodera
Y
Nakazawa
S
Ariyoshi
Y
Takahashi
T
Ueda
R
Two distinct portions of LTG19/ENL at 19p13 are involved in t(11; 19) leukemia.
Oncogene
8
1993
2617
28
Chomczynski
P
Sacchi
N
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal Biochem
162
1987
156
29
Wessels
JW
Mollevanger
P
Dauwerse
JG
Cluitmans
FHM
Breuning
MH
Beverstock
GC
Two distinct loci on the short arm of chromosome 16 are involved in myeloid leukemia.
Blood
77
1991
1555
30
Yamamoto
K
Seto
M
Iida
S
Komatsu
H
Kamada
N
Kojima
S
Kodera
Y
Nakazawa
S
Saito
H
Takahashi
T
Ueda
R
A reverse transcriptase-polymerase chain reaction detects heterogeneous chimeric mRNAs in leukemias with 11q23 abnormalities.
Blood
83
1994
2912
31
Kuriyama
M
Harada
N
Kuroda
S
Yamamoto
T
Nakafuku
M
Iwamatsu
A
Yamamoto
D
Prasad
R
Croce
C
Canaani
E
Kaibuchi
K
Identification of AF-6 and Canoe as putative targets for Ras.
J Biol Chem
271
1996
607
32
Shilatifard
A
Lane
WS
Jackson
KW
Conaway
RC
Conaway
JW
An RNA polymerase II elongation factor encoded by the human ELL gene.
Science
271
1996
1873
33
Corral
J
Lavenir
I
Impey
H
Warren
AJ
Foster
A
Larson
TA
Bell
S
McKerzie
ANJ
King
G
Rabbitts
TH
An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes.
Cell
85
1996
853
34
Yang
X-J
Ogryzko
VV
Nishikawa
J
Howard
BH
Nakatani
Y
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.
Nature
382
1996
319
35
Miller
RW
Rubinstein
JH
Tumors in Rubinstein-Taybi syndrome.
Am J Med Genet
56
1995
112
36
Ogryzko
VV
Schiltz
RL
Russanova
V
Howard
BH
Nakatani
Y
The trascriptional coactivators p300 and CBP are histone acetyltransferases.
Cell
87
1996
953
Sign in via your Institution